Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?

Marčec, Robert; Dodig, Vinko Michael; Likić, Robert

doi:10.1016/j.jinf.2022.10.030

Cited by 1 publication

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…patients treated with regdanvimab compared to those receiving no regdanvimab. This finding is in line with Marcec et al 36 who found that the use of regdanvimab in patients with COVID-19 is not associated with a significant benefit in mortality rate. However, other metaanalyses [37][38][39] have indicated that mAb treatments may reduce mortality rate in patients with COVID-19 infection.…”

Section: Discussionsupporting

confidence: 91%

Efficacy and safety of regdanvimab in patients with mild to moderate COVID‐19: A rapid review and meta‐analysis

Amani

2023

Brit J Clinical Pharma

View full text Add to dashboard Cite

for the treatment of confirmed COVID-19 disease.Methods: Cochrane Library, PubMed, medRxiv and Google Scholar were searched for relevant evidence up to October 27, 2022. The quality of included studies was assessed using the Cochrane risk of bias tools. Data were analysed using RevMan software.Results: Eight studies involving 4793 patients were included. A significant difference was observed between the regdanvimab and no-regdanvimab groups in terms of length of hospital stay (mean difference [MD] = À1.15, 95% confidence interval [CI]:À1.80 to À0.43), clinical recovery (odds ratio [OR] = 2.09, 95% CI: 1.38 to 3.18), disease progression (OR = 0.23, 95% CI: 0.16 to 0.33), the need for oxygen therapy (OR = 0.33, 95% CI: 0.25 to 0.43) and duration of oxygen therapy (MD = À3.00, 95% CI: À4.44 to À1.56). However, no significant difference was detected between 2 groups regarding mortality rate (OR = 0.46, 95% CI: 0.11 to 1.89), need for mechanical ventilation (OR = 0.39, 95% CI: 0.08 to 1.89) and hospital admission rate (OR = 0.61, 95% CI: 0.35 to 1.03). The incidence of adverse events was similar in both groups (OR = 0.96, 95% CI: 0.77 to 1.18). Conclusion:Regdanvimab was not effective in reducing mortality and hospital admission rate in patients with mild to moderate COVID-19, but it was effective in improving other efficacy outcomes. Further research is needed to confirm these findings.

show abstract

Section: Discussionsupporting

confidence: 91%

Efficacy and safety of regdanvimab in patients with mild to moderate COVID‐19: A rapid review and meta‐analysis

Amani

2023

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?

Cited by 1 publication

References 2 publications

Efficacy and safety of regdanvimab in patients with mild to moderate COVID‐19: A rapid review and meta‐analysis

Efficacy and safety of regdanvimab in patients with mild to moderate COVID‐19: A rapid review and meta‐analysis

Contact Info

Product

Resources

About